CN107261116A - 一种促进组织再生修复剂 - Google Patents

一种促进组织再生修复剂 Download PDF

Info

Publication number
CN107261116A
CN107261116A CN201710460044.6A CN201710460044A CN107261116A CN 107261116 A CN107261116 A CN 107261116A CN 201710460044 A CN201710460044 A CN 201710460044A CN 107261116 A CN107261116 A CN 107261116A
Authority
CN
China
Prior art keywords
laminin
dihydrogen phosphate
sodium dihydrogen
promotion organization
repair agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710460044.6A
Other languages
English (en)
Inventor
张淼
孙世龙
胡恩栋
赵泽
王志英
翟婧杙
于文斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Eln Biotechnology Co Ltd
Original Assignee
Henan Eln Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Eln Biotechnology Co Ltd filed Critical Henan Eln Biotechnology Co Ltd
Priority to CN201710460044.6A priority Critical patent/CN107261116A/zh
Publication of CN107261116A publication Critical patent/CN107261116A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及一种促进组织再生修复剂，所述修复剂以层粘连蛋白为主要成分，加入生理盐水和磷酸二氢钾为辅料制作而成，所述各成分含量配比为：层粘连蛋白0.5‑10mg/ml、生理盐水2‑5份、磷酸二氢钠1‑3份，所述磷酸二氢钠为食品级磷酸二氢钠；本发明的优点是利用层粘连蛋白自身的多肽链上的功能区促进导向细胞迁移粘连。

Description

一种促进组织再生修复剂
技术领域
本发明属于生物医药技术领域，具体涉及一种促进组织再生修复剂。
背景技术
层粘连蛋白主要存在于基膜(basal lamina)结构中，是基膜所特有的非胶原糖蛋白,相对分子质量为820kDa，含13-15%的糖,有三个亚单位，即重链(α链,400kDa)和β1(215kDa)、β2(205kDa)两条轻链，结构上呈现不对称的十字形，由一条长臂和三条相似的短臂构成，这四个臂均有棒状节段和球状的末端域，β1和β2短臂上有两个球形结构域，α链上的短臂有三个球形结构域，其中有一个结构域同Ⅳ型胶原结合，第二个结构域同肝素结合，还有同细胞表面受体结合的结构域，正是这些独立的结合位点使LN作为一个桥梁分子，介导细胞同基膜结合；所以LN的主要功能就是作为基膜的主要结构成分对基膜的组装起关键作用，在细胞表面形成网络结构并将细胞固定在基膜上；LN还有许多其他的作用，如在细胞发育过程中刺激细胞粘着、细胞运动；LN还能够刺激胚胎中神经轴的生长，并促进成年动物的神经损伤后重生长和再生；如同纤粘连蛋白，细胞外的LN能够影响细胞的生长、迁移和分化；LN在原生殖细胞的迁移中起关键作用。
目前，由于人类血缘传染病因子的难以控制和人类血液的资源少，在细胞再生方面难以研制出有效的组织再生修复功能的药剂，所以利用LN在细胞再生领域的应用开发还是一个空白。
发明内容
本发明的目的是为了克服上述技术方面的不足，而研制出的专门针对细胞组织再生修复剂。
本发明的目的是这样实现的：一种促进组织再生修复剂，所述修复剂以层粘连蛋白为主要成分，加入生理盐水和磷酸二氢钾为辅料制作而成。
所述各成分含量配比为：层粘连蛋白0.5-10mg/ml、生理盐水2-5份、磷酸二氢钠1-3份。
所述磷酸二氢钠为食品级磷酸二氢钠。
本发明的有益效果：本发明的优点是利用层粘连蛋白自身的多肽链上的功能区促进导向细胞迁移粘连；细胞通过连结层粘连蛋白的多肽部位，再由层粘连蛋白的肽链与胶原结合，从而使细胞粘附于基底膜基质上；从而促进组织的修复再生。
具体实施方式
实施例1
一种促进组织再生修复剂，所述修复剂以层粘连蛋白为主要成分，加入生理盐水和磷酸二氢钾为辅料制作而成；将层粘连蛋白5mg/ml、生理盐水3份、磷酸二氢钠2份充分混合，制成水剂，封装在无菌瓶中，应用时候直接擦涂。
实施例2
将产品制成膏剂
将层粘连蛋白5mg/ml、生理盐水1份充分混合，然后加入磷酸二氢钠1份冷却后制成膏剂，然后进行无菌包装，使用的时候直接涂抹在伤口处。
综上所述：由于LN的主要功能就是作为基膜的主要结构成分对基膜的组装起关键作用, 在细胞表面形成网络结构并将细胞固定在基膜上；LN还有许多其他的作用，如在细胞发育过程中刺激细胞粘着、细胞运动；LN还能够刺激胚胎中神经轴的生长，并促进成年动物的神经损伤后重生长和再生；如同纤粘连蛋白，细胞外的LN能够影响细胞的生长、迁移和分化；LN在原生殖细胞的迁移中起关键作用；本发明的优点是利用层粘连蛋白自身的多肽链上的功能区促进导向细胞迁移粘连；细胞通过连结层粘连蛋白的多肽部位，再由层粘连蛋白的肽链与胶原结合，从而使细胞粘附于基底膜基质上；从而促进组织的修复再生。
具体实施方式是对本发明的进一步说明而非限制，对本领域普通技术人员来说在不脱离本发明实质内容的情况下对结构做进一步变换，而所有这些变换都应属于本发明所附权利要求的保护范围。

Claims (3)

1.一种促进组织再生修复剂，其特征在于：所述修复剂以层粘连蛋白为主要成分，加入生理盐水和磷酸二氢钾为辅料制作而成。
2.根据权利要求1所述的一种促进组织再生修复剂，其特征在于：所述各成分含量配比为：层粘连蛋白0.5-10mg/ml、生理盐水2-5份、磷酸二氢钠1-3份。
3.根据权利要求1和2所述的一种促进组织再生修复剂，其特征在于：所述磷酸二氢钠为食品级磷酸二氢钠。
CN201710460044.6A 2017-06-17 2017-06-17 一种促进组织再生修复剂 Pending CN107261116A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710460044.6A CN107261116A (zh) 2017-06-17 2017-06-17 一种促进组织再生修复剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710460044.6A CN107261116A (zh) 2017-06-17 2017-06-17 一种促进组织再生修复剂

Publications (1)

Publication Number Publication Date
CN107261116A true CN107261116A (zh) 2017-10-20

Family

ID=60067729

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710460044.6A Pending CN107261116A (zh) 2017-06-17 2017-06-17 一种促进组织再生修复剂

Country Status (1)

Country Link
CN (1) CN107261116A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111135111A (zh) * 2018-11-06 2020-05-12 王丛飞 一种层黏连蛋白皮肤修复剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260086A1 (en) * 2002-04-01 2003-10-20 Board Of Regents, The University Of Texas System Composite material for wound repair
CN101873854A (zh) * 2007-10-09 2010-10-27 内华达高等教育系统董事会,代表内华达大学雷诺校区 层粘连蛋白、衍生物和包含它们的组合物以及它们的治疗性应用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260086A1 (en) * 2002-04-01 2003-10-20 Board Of Regents, The University Of Texas System Composite material for wound repair
CN101873854A (zh) * 2007-10-09 2010-10-27 内华达高等教育系统董事会,代表内华达大学雷诺校区 层粘连蛋白、衍生物和包含它们的组合物以及它们的治疗性应用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111135111A (zh) * 2018-11-06 2020-05-12 王丛飞 一种层黏连蛋白皮肤修复剂及其制备方法

Similar Documents

Publication Publication Date Title
Sassoli et al. Combined use of bone marrow-derived mesenchymal stromal cells (BM-MSCs) and platelet rich plasma (PRP) stimulates proliferation and differentiation of myoblasts in vitro: new therapeutic perspectives for skeletal muscle repair/regeneration
Horie et al. Oxidized galectin-1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy
Middleton et al. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries
Del Bue et al. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo
AU2013343685B2 (en) Collagen hydrolyzate and use thereof
Cazzolli et al. The crystalloid‐colloid debate: consequences of resuscitation fluid selection in veterinary critical care
AR109513A2 (es) Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende
Mann et al. The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19
ES2709324T3 (es) Polvo de colágeno, composición y uso
Onoda et al. Joint haemorrhage partly accelerated immobilization-induced synovial adhesions and capsular shortening in rats
CN107261116A (zh) 一种促进组织再生修复剂
KR101380147B1 (ko) 젤라틴 함유 국소 조성물
WO2013136871A1 (ja) 過硫酸化コンドロイチン組成物
CN106215239A (zh) 一种交联抗菌型脱细胞基质材料的制备方法
EP0994716B1 (en) Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body
Uchida et al. Enhancement of periosteal bone formation by basic fibroblast‐derived growth factor containing polycystic kidney disease and collagen‐binding domains from Clostridium histolyticum collagenase
Shirbhate et al. Fibronectin and Its Applications in Dentistry and Periodontics: A Cell Behaviour Conditioner
CN101842026B (zh) 骨强化用食品原材料
Tonogai et al. Platelet-rich plasma does not reduce skeletal muscle fibrosis after distraction osteogenesis
Janssen et al. Inhalation therapy for repairing damaged elastin fibers and decelerating elastinolysis in chronic obstructive pulmonary disease
McDonald et al. Regulation of myofilament contractile function in human donor and failing hearts
Walsh et al. Capillary leak and edema after resuscitation: The potential contribution of reduced endothelial shear stress caused by hemodilution
JP2015520223A (ja) 炎症性疾患の局所処置に使用するため脱水した鶏卵卵白を含む組成物
Dhalla et al. Calcium transport by the subcellular particles of the skeletal muscle of genetically dystrophic hamster
Ai et al. Adolescent Binge Alcohol Exposure Affects Cardiovascular Function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171020

RJ01 Rejection of invention patent application after publication